Talphera TLPH Q2 2025 Earnings Call Transcript

Talphera (TLPH) updated investors on its nafamostat mesylate clinical trial at the H.C. Wainwright conference. The NEPHRO study is 75% enrolled, with topline data expected in early 2025 and a potential U.S. launch in late 2025. The FDA reduced the study size to 70 patients, maintaining 90% statistical power. New guidelines recommend nafamostat, and the company sees a larger U.S. market opportunity. The stock has gained 56% over six months, with analysts setting price targets between $3 and $3.50

Talphera (Nasdaq: TLPH) reported Q2 2026 results and a corporate update on nafamostat. NEPHRO CRRT study enrollment is 75%, expected to finish by year-end. KDIGO 2026 draft guidelines cite nafamostat as an acceptable CRRT anticoagulant. Cash and investments were $17.1M at June 30, 2026; Q2 net loss was $4.3M.

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a posi

Nvidia is financing AI projects, offering $500B in off-balance-sheet guarantees. CEO Jensen Huang aims to fund demand, citing strong interest. Nvidia's revenue hit $216B in FY2024, with $70B in free cash flow. Partners like CoreWeave face credit tightening, with shares down 30%. Nvidia's stock fell 7.6% in October, raising concerns about demand meeting expectations.

AstraZeneca's Imfinzi and Amgen's Imdelltra combination therapy extended survival by eight months in advanced lung cancer patients, reducing death risk by 58% according to a trial. Side effects were manageable, with 1% experiencing neurological issues. AstraZeneca also reported positive bladder cancer data for Imfinzi plus Pfizer's Padcev. Both studies were presented at an oncology meeting in Madrid.

A Phase III trial showed that intismeran autogene, a personalized mRNA therapy, combined with pembrolizumab, reduced the risk of death or recurrence by 42% in high-risk melanoma patients. The study, presented at ESMO 2026, enrolled 1,137 patients and demonstrated improved recurrence-free and distant metastasis-free survival. Despite the positive clinical results, a data leak caused shares of manufacturers Moderna and Merck to fall.